Why JXJT Makes the Next Candidate for a TOP like-pop

Last week out of nowhere, TOP Financial Group Limited (TOP) rose from $7 to as high as $250. As a result, a bunch of Chinese and Hong Kong-related listings followed suit on Friday, including Huadi International Group Co., Ltd. (HUDI), Magic Empire Global Limited (MEGL), Dunxin Financial Holdings Limited (DXF), Jiuzi Holdings, Inc. (JZXN), Top KingWin Ltd (TCJH), Baosheng Media Group Holdings Limited (BAOS), Addentax Group Corp. (ATXG), WeTrade Group, Inc. (WETG), Tian Ruixiang Holdings Ltd (TIRX), Leju Holdings Limited (LEJU), AGBA Group Holding Limited (AGBA),  Lichen China Limited (LICN), Uxin Limited (UXIN), Golden Sun Education Group Limited (GSUN),  Powerbridge Technologies Co., Ltd. (PBTS), U Power Limited (UCAR), WANG & LEE GROUP, Inc. (WLGS), Smart Powerr Corp. (CREG) and AMTD Digital Inc. (HKD). One stock that we think stands out of this list is JX Luxventure Limited (JXJT). It increased a relatively muted 12% to $5.95 on Friday but did hit as high as $8.64, proving its ability to really move. 

Edit May 1: JXJT ran 100% today, proving that it can move large. It was one of the biggest Chinese/Hong Kong gainers today long with BAOS, LEJU, Quhuo Limited (QH), GD Culture Group Limited (GDC), UTime Limited (UTME), Sentage Holdings Inc. (SNTG) and Tantech Holdings Ltd (TANH) while many of the stock listed above experienced significant pullbacks today. 

What makes JXJT so special? It has characteristics that make it extremely similar to TOP. First off, after a recent reverse split, shares outstanding are only 6 million. The stock's float is less than 700,000 as insider ownership is 85%, nearly identical to TOP's 86%. Some of the Chinese pumps fizzled out last week, and what people don't understand is that the stocks that move at a sustained and massive level always have very high percentages of insider ownership, at least 80%. 

More evidence to suggest a move on JXJT is possible is by looking at the volume. It only had 323,000 shares traded on Friday and trades well less than 100,000 shares on any given day. Up until the beginning of April, TOP also traded well less than 100,000 shares on most days, and even with the pickup in volume traded around a million shares right before it blew up. When looking at MEGL, it traded less than 100,000 shares in a day. Then traded 10 million shares on Thursday without any movement before exploding over 300% on over 100 million shares traded the next day. HUDI has the most similar pattern to JXJT, with less than 100,000 in daily volume traded up until Thursday when it had 414,000 shares traded on a flat stock price before exploding nearly 400% on over 50 million in volume on Friday. These are the types of stocks you needing to be looking at. Low float, low volume, high insider ownership. JXJT matches all of this. 

JXJT is also financially a pretty strong company for a market cap of $36 million and probably deserves a higher market cap just on fundamentals. (Link to financials here) 

Revenue has jumped from $13 million to $52 million in six months of operations from 2021 to 2022. Net loss is $20 million for those six months but most of that is in share-based payments as a new management team took over the listing. The operating cash flow loss is only $3 million. The balance sheet is very strong with $31 million in assets ($11 million in cash) against only $9 million in liabilities. This company is in no need to dilute after the new management team took over much of the shares. 

This makes JXJT an ideal candidate to go on massive run on multiple fronts. 











Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more